Hematologic (Blood) Cancer Overview
Hematologic (Blood) Cancer
Under the leadership of UVA Cancer Center Director, Dr. Thomas Loughran, and Hematology/Oncology Division Chief, Dr. Michael Williams, UVA has accelerated its expertise in the treatment of cancers of the blood, marrow and lymphatic systems, including acute and chronic leukemia, LGL leukemia, Hodgkin lymphoma, non-Hodgkin lymphoma, multiple myeloma and other rare hematologic malignancies.
LGL Leukemia Program & Registry
Led by UVA Cancer Center director and LGL leukemia founder, Thomas P. Loughran, Jr., the LGL Leukemia Program at UVA offers patients access to advanced treatment options, clinical trials and participation in the LGL Leukemia Registry, a research database exclusive to UVA. The registry and other efforts to better understand and treat the disease are ongoing and are a priority of the cancer center. Patients with LGL leukemia and their physicians are encouraged to contact the LGL clinic for appointment information or instructions to enroll in the registry. Travel assistance is available for patients who qualify.
Advanced Treatments & Therapies
Dramatic advances have been made in recent years for most hematological cancers because of research. Novel targeted therapies, which complement or replace traditional chemotherapy and radiation treatments, are now routine for many hematological malignancies. We offer clinical trials for these disorders, with a focus on immunotherapy, targeted agents and new chemotherapy treatments.
UVA Hematologic Cancer Services
Multi-Disciplinary Team of Hematology Experts
From hematopathologists, experts in identifying and diagnosing blood cancer, to hematologists, dedicated nurses and social workers, patients receive comprehensive care for their conditions. The cytogenetic and other hematology/oncology labs at UVA specialize in running tests that are critical in the diagnosis and treatment of rare and common blood cancers. Patients with these conditions often need long-term follow up and care which is a priority of the hematology team at the UVA Cancer Center.
UVA offers the latest in targeted therapies including immunotherapy, which are antibody-based medicines, and novel agents such as tyrosine kinase inhibitors and immune-modulating agents. Patients at UVA have the benefit of access to clinical trials not offered at other cancer centers in the area as well as the latest in FDA-approved treatments as they are released.
For Patients with Advanced Disease
UVA Stem Cell Transplant Program
For patients with high-risk and life-threatening blood diseases, UVA Cancer Center's Stem Cell Transplant Program provides additional treatment options that increase the likelihood of survival.